GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » N4 Pharma PLC (STU:0GO) » Definitions » Institutional Ownership

N4 Pharma (STU:0GO) Institutional Ownership : 0.22% (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is N4 Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, N4 Pharma's institutional ownership is 0.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, N4 Pharma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, N4 Pharma's Float Percentage Of Total Shares Outstanding is 0.00%.


N4 Pharma Institutional Ownership Historical Data

The historical data trend for N4 Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

N4 Pharma Institutional Ownership Chart

N4 Pharma Historical Data

The historical data trend for N4 Pharma can be seen below:

2021-12-31 2022-01-31 2022-02-28 2022-03-31 2022-04-30 2022-05-31 2022-06-30 2022-07-31 2022-08-31 2022-09-30
Institutional Ownership 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22 0.22

N4 Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


N4 Pharma (STU:0GO) Business Description

Traded in Other Exchanges
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
N4 Pharma PLC is the holding company for N4 UK. N4 UK is a specialist pharmaceutical company engaged in the development of nanoparticle silica delivery systems to improve the cellular delivery and potency of cancer treatments and vaccines. The company operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec.

N4 Pharma (STU:0GO) Headlines

No Headlines